LAM aims to apply methylation cancer testing to blood
The cancer blood testing company Laboratory for Advanced Medicine is ready to compete on price, which might be necessary in a market already thronged with products.
Deals and data in the offing for Oncimmune
Oncimmune is not the only company looking to use the immune system to diagnose cancer. But its growth plans are intense, and it intends to prove the economic benefits of…
Boehringer’s digital drive starts bearing fruit
Less than two years after setting up its BI X digital lab, Boehringer Ingelheim is ready to start clinical trials of a programme monitoring speech patterns to diagnose…
AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
AACR 2019 – Guardant looks to its other liquid biopsy
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.
ACC 2019 preview – Detection vs diagnosis: Irhythm and the Apple Watch
Will the Apple Heart Study allow early detection of arrhythmias, or drive the worried well to doctors unnecessarily? For Irhythm Technologies, either is a good outcome.
Oncocyte banks on a new kind of liquid biopsy
The Biotime-backed group believes it can use immune system gene expression levels to detect lung cancer earlier. But another trial will be necessary before the test can…
Check-Cap auditions for its screen debut
Check-Cap has a new spin on capsule endoscopy, using X-rays instead of a visual camera. But more compelling clinical data will be necessary if it is to position its…
Illumina bets on Pacific, not nanopores
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.